Late life Depression: Prevalence, Pathogenesis, Clinical Presentation, Evaluation and Emerging Therapeutics
Hany I. Hassanin, MD

Geriatrics and Gerontology, Faculty of Medicine, Ain Shams University, Egypt.
Correspondence: h.ibrahim.ger@gmail.com

Depression is the prototype of mood disorders in older adult, however; it is not a feature of normal ageing, and rather it is a painful emotional experience characterized by loss of interest or pleasure in life enough to cause functional impairment. (1) It is a major public health problem; and a common cause of emotional distress and poor quality of life among older adults. Depression increases the perceived disability of comorbid physical illnesses. Moreover, it is associated with increased all-cause mortality. (2)

The clinical symptoms and causes differ considerably between elderly who are diagnosed with depression late in life and patients who experience a recurrence of preexisting illness late in life. (3) However, there is no consensus regarding the age used to differentiate between the late- and early-onset depression. In the USA 50 years of age is the used cut off and in UK the age of 60 is the used one. (4)

Prevalence of depressive disorders among elderly:

The prevalence of depression among elderly varies according to the used diagnostic criteria. Indeed, depression is a group of different clinical entities. The depressive disorders listed in the Diagnostic and Statistical Manual of Mental Disorders, 5th editions (DSM-V) can be distinguished from one another by different symptoms and signs. The depressive disorders include major depressive disorder, dysthymic disorder, bipolar disorder and mood disorder due to a general medical condition. Adjustment disorder with depressed mood may also be considered a form of depression. (5) For community dwelling elderly, the prevalence of major depression ranges from 1% to 5%. The other depressive symptoms are present in 15% of the elderly in the community setting. Rates of depression are higher in older women than in older men, but this gender gap disappears among the oldest old. Rates of major depression among older adults are higher in other settings e.g. medical outpatients (5-10%), medical inpatients (10-12%), and residential care facilities (14 to 42%). (6)

Risk factors of late life depression:
Complex biological, psychological, and social factors are linked to the development of depression among older adults. (7)

Genetics
Genetic susceptibility to depression in late life (DLL) is an attractive theory that explains why some older persons are predisposed to depression. But specific genetic markers for late onset type have not been identified yet. On the other hand, genetic factors are found to play a great role in the development of the early onset depression in elderly. These factors include the serotonin transporter (5HTTLPR) gene, apolipoprotein E (ApoE) gene, brain-derived neurotrophic factor (BDNF) gene, and 5-methyltetrahydrofolate reductase (MTHFR) gene. Moreover, these genes may be involved in the treatment response of depression in later life. (7)

Non-genetic biological risk factors:
These biological risks include endocrine, inflammatory or immune, cardiovascular, and brain circuits’ factors. (6)
a) Link between immune system and DLL

Several studies focused on acquired immune responses in patients suffering from depression (e.g., T- and B-cell functions, which were generally found to be suppressed), more recent research suggests that a significant percentage of depressed patients may experience activation of the innate immune response. (8-10)

A marked breakthrough in terms of the recognition of the potential contribution of immunity to depression has been demonstrated that all cardinal features of inflammation are apparent in patients with major
depression. Elderly with late life depression have been found to exhibit significant elevations of innate immune cytokines and their soluble receptors not only in peripheral blood but also in cerebrospinal fluid (CSF). Also, they exhibit elevations in acute-phase reactants, chemokines, and adhesion molecules as well as inflammatory mediators such as the prostaglandins. (11)

A meta-analysis had been conducted and indicated that inflammatory markers elevations like IL-6 and CRP were linked to more association with depressive symptoms. (12) Additionally, correlations between the severity of depressive symptoms and increased peripheral inflammatory cytokines have been observed. (13) However, the link between inflammatory markers and specific behavioral changes is still under investigation, it should be noted that easy fatigue, loss of energy, and psychomotor retardation are some of the most common symptoms after cytokine administration. (14, 15)

b) Neurotransmitter Dysfunction and DLL

Dysfunction in serotonergic, noradrenergic, and dopaminergic neurotransmission has been demonstrated in DLL. Evidence exists that the age-related changes of the neurotransmitters make older persons more susceptible to depression. It is a fact that the antidepressant medication targeting serotonin and noradrenaline function improves depressive symptoms. (7)

c) The Role of Stress

Abnormalities of the HPA axis in depressed patients are well described. Overt dysregulation is found only in a subset of depressed patients. As articulated by Nemeroff and his colleagues depression and early psychological trauma converge at the level of HPA-axis regulation. (16) Adversity that occurs early in life specially if severe and/or prolonged seems to contribute significantly both to subsequent risk for anxiety and depressive disorders and to HPA dysfunction. Physical, psychological, sexual abuse traumas or the loss of beloved person that occur during critical periods of development result in a permanent alteration of stress reactivity in the central nervous system with subsequent increased vulnerability to later psychiatric disorders. (17)

Actually, the maintenance of activated stress response system following chronic or severe stress makes adaptive sense and high threat intensity resulting in persistent elevated “alert” status. This stress reactivity could explain the findings of high levels of HPA-axis activity, including elevated peripheral cortisol (18, 19) and central corticotrophin-releasing hormone (20, 21) in some depressed elderly.

d) Brain circuits and DLL

Dysfunction of certain areas or circuits of the brain are related to the development and the prognosis of DLL. These areas include the dorsolateral prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, subcortical white matter, basal ganglia (especially striatum), and the hippocampus. (7) Regional cerebral blood flow and cerebral metabolism studies have demonstrated that the dorsal cingulate gyrus, middle and dorsolateral prefrontal cortex (DLPFC), insula, and superior temporal gyrus are all hypoactive at rest during negative mood states and that their activity increases with selective serotonin reuptake inhibitor treatment. (22)

e) The Bidirectional Relationship Between Depression And Comorbidities

There is no doubt that advanced aging carries a high probability of other medical and/or psychiatric disorders. Depression as one of the most common psychiatric illnesses in elderly population has a unique bidirectional relation with other comorbid conditions including prevalence, prognosis, and response to standard medications or even selection of pharmacotherapy. Almost any serious or chronic condition can produce a depressive reaction; the disorders that are most strongly associated with depression include cardiac conditions and neurologic illness, including cerebrovascular disease. Specific medical conditions that may be associated with geriatric depression include myocardial infarction, coronary heart disease, cardiac catheterization, diabetes, and obesity. (7) Nemeroff and Owens (23) summarized the biologic underpinnings of depression and categorized this into 3 general systems of altered function: the monoamine neurotransmitter systems, the cardiovascular system and disturbance in the hypothalamic-pituitary-adrenal (HPA) axis. These systems are also involved in various common medical disorders. Now we will review few examples about some commonly distributed medical problems in elderly and its interaction with late life depression.

Late-Life Depression and Cardiovascular Disorders in Older Adults.

In the last five decades, many studies have revealed a link between the incidence of depression and cardiovascular morbidity and mortality. Even after controlling for other possible confounders, like age, smoking and other behavioral and medical cofactors, depression appears to increase the risk for ischemic heart diseases (by 1.5-fold to 2.0-fold), as well as
death from cardiac diseases. The severity of depression has consistently been shown to predict
sequels, readmission, increases the frequency of cardiac events and negatively correlates with the
functional benefits from coronary artery bypass grafting.

Moreover, many studies have indicated surprising results that 16% to 18% of admitted patients after an
acute myocardial infarction (AMI) are prone to major depression, and about 30% of them experience
depression during the first 12 months after infarction, especially in the first 6 months. Major depressive
disorder has been associated with increased mortality by 3.5-fold in the first 24 weeks following an AMI, and
2.0-fold over 6.7 years of follow-up.

Late-Life Depression and Common Endocrinial Disorders

Endocrine system undergoes multiple age related changes that could contribute to multiple
psychological and behavioral disturbances. Several studies indicated that subclinical hypothyroidism can be
present in about 23% of the elderly. Many cases of subclinical hypothyroidism pose variable degrees of
depressive symptoms either de novo or exacerbation of preexisting symptoms.

Many symptoms of depression in later life could be bidirectional, with age-related endocrine changes, such
as low serum levels of estrogen or testosterone. However, more than 70% of men above 70 years have
free levels of testosterone consistent with hypogonadism. Low testosterone in men is associated with depression, fatigue, hot flushes, sweating, and weight gain, as well as, low muscle mass, increased fat mass, low muscle power, anemia, and osteoporosis.

Late-Life Depression and medications:
Many drugs are associated with depressive disorders (such as beta blockers, CNS medications, calcium
channel blockers, digitalis, corticosteroids, hormones, anti-Parkinson agents, respiratory or gastrointestinal
medications, certain cancer medications, benzodiazepines and interferon).

Late-Life Depression and Chronic Obstructive Pulmonary Disease
Depression frequently coexists with COPD, with prevalence of comorbid depression varying from 10% to
42%, with the highest prevalent of depression in those who are on domiciliary oxygen. However, comorbid depression is frequently associated with lower physical activity, lower compliance to medications, increased hospital admission and mortality, dyspnea, easy fatigability, and disability in those with COPD, even after adjustment of severity of illness.

More than 80% of patients with COPD are smokers, and smokers are more likely to either restart smoking or
heavily smoke during periods of exacerbation, which in turn may worsen respiratory status. Increased
risk of alcohol abuse by depressed patients with COPD may put such patients at increased risk of severe
community-acquired pneumonia, particularly aspiration pneumonia.

Many patients with COPD who developed depressive symptoms passed undiagnosed because of several
causes such as limited awareness by both patients and health care providers of this comorbidity; limited
resources, time during provider visits; and misinterpretation of depressive symptoms as symptoms of
COPD.

There is a big challenge in this issue as symptoms of depression and COPD widely overlap and special
attention must be taken to avoid mistaking symptoms of depression and worsening of COPD and vice versa,
but sustained depressed mood or anhedonia should not be attributed to lung disease alone. Indeed, Loss of
energy, memory impairment and lack of concentration, weight loss, and sleep disturbances can be common
symptoms in either depression or COPD.

Relationship of late-life depression and cognitive impairment
Memory impairment and depression were linked in many previous studies, the cognitive impairment related to depression was thought to be reversible, and now evidence suggests the presence of longer-lasting effects.

Moreover, 40% of individuals developed late onset major depression with cognitive impairment are at risk
of developing AD within three to five years.

Symptoms of depression are usually present in dementia and may occur in (40%–50%) of patients
with AD. It occurs more commonly as a symptom in vascular dementia than in Alzheimer dementia.

Relationship of late-life depression and Neurologic disorders
The prevalence of depressive disorders is high among elderly patients suffering from cerebrovascular disease and other neurologic disorders. The prevalence rate for major depression is 19.3% among hospitalized patients and 23.3% in outpatients with stroke.
The prevalence of major depression varies from 7.7% to more than 25% in outpatient samples with PD.
Other depressive symptoms occur in approximately half of the patients with PD causing substantial
functional impairment.

Depression in PD is not a reaction to psychosocial stress and disability. It is secondary to the underlying
neuroanatomical degeneration, leading to changes in the central serotonergic function and in
neurodegeneration of specific cortical and subcortical
pathways. Depression in PD is usually mild and less frequently associated with dysphoria, anhedonia, feelings of guilt, and loss of energy but is associated with more concentration problems than depression in older adults without neurologic disease. 

**Psychosocial Factors and Personality**

Many psychological factors are associated with depression. Neuroticism is a personality trait characterized by worry, fear, anxiety, guilt, and moodiness. People with a high level of neuroticism can be prone to DLL. While, high levels of mastery of one’s environment and self-efficacy provide protection against DLL as shown in table (1). Aging is associated with progressive losses including withdrawal from work, loss of purpose, reduced independence, loss of friends, increased poverty, the risk of developing an illness leading to learned helplessness, and subsequently occurrence of DLL. 

<table>
<thead>
<tr>
<th>Biological risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Genetic susceptibility - female sex</td>
</tr>
<tr>
<td>2. Under activity of serotonergic, noradrenergic neurotransmission</td>
</tr>
<tr>
<td>3. Dysregulation of HPA axis</td>
</tr>
<tr>
<td>4. Hypogonadism, excess cortisol, and hypothyroidism</td>
</tr>
<tr>
<td>5. Acute phase reactant</td>
</tr>
<tr>
<td>6. Vascular diseases</td>
</tr>
<tr>
<td>7. Dementia</td>
</tr>
<tr>
<td>8. Other medical conditions (COPD, DM,..)</td>
</tr>
<tr>
<td>9. Other neurological conditions (stroke, PD,..)</td>
</tr>
<tr>
<td>10. Medications (beta blockers, CNS medications, calcium channel blockers, digitalis, corticosteroids,.......)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Psychosocial risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. Neuroticism</td>
</tr>
<tr>
<td>12. learned helplessness</td>
</tr>
<tr>
<td>13. Cognitive distortions</td>
</tr>
<tr>
<td>14. External locus of control</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Social risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. Stressful life events and daily hassles</td>
</tr>
<tr>
<td>16. Bereavement</td>
</tr>
<tr>
<td>17. Socio-economic disadvantage</td>
</tr>
<tr>
<td>18. Impaired social support</td>
</tr>
</tbody>
</table>

**Symptomatic Differences in the Elderly:**

The Diagnostic criteria for different types of mood disorders are the same for the elderly and the young, however; symptom expression can be age dependent. Depressed mood, which is the cardinal symptom of depression, may be less prominent in depression in old age making early recognition of late-onset depression difficult for health care providers. Early onset depression is usually characterized by longer duration of symptoms, a personal history of depressive episodes, a serious suicide attempt, childhood events, a family history of depression, and high neuroticism. On the other hand, the late onset depression is usually associated with poor appetite, weight loss, psychomotor change, anhedonia and cognitive deficit. 

Vascular depression usually presents with apathy, psychomotor retardation, poor executive function, less depressive thinking (such as guilt or unworthiness), and a late age at onset.

Compared to young patients, elderly people with new or recurrent depression are more hypochondriacal, delusional, and tend to present more with symptoms of psychomotor change, anhedonia, cognitive impairments.

The terms “masked depression” and “depressive equivalents” are sometimes used to describe older patients who do not appear depressed but manifest physical symptoms such as chronic pain, fatigue, or hypochondriasis. There is a higher incidence of minor depression than major depressive disorder in the elderly.

**Suicidal behavior in DLL:**

There is an age related rise in the rate of suicide in patients with depression. Moreover, a suicidal attempt can be the initial presentation of DLL. Increased risk of suicide may be related to multiple chronic medical conditions, insomnia, and lack of social support. As with patients of all ages, worsening suicidal ideation may indicate hospitalization and ECT.

**Sleep and DLL:**

Major depression at any age is associated with sleep problems both insomnia and hypersomnia, however, aging itself increases the prevalence of insomnia. Insomnia is a risk factor for first and recurrent episodes of depression. Early morning awakening is common in older depressed patients. 

Ageing is associated with phase advance in the rest-activity cycle. Starting from the third decade, the sleeping period starts earlier. Among depressed patients with insomnia, the midpoint of the sleep period advances 4 minutes earlier for each year of age. Treating the sleep problems in DLL should focus on an earlier bedtime and an earlier rising time. 

**Who Should Be Screened for Depression?**

The U.S. Preventive Services Task Force (USPSTF) supports depression screening in primary care settings for adults, including older adults, if there is adequate treatment with antidepressants, therapy or a combination of both available. Many validated tools exist for initial depression screening in later life e.g. The PHQ-9 and GDS. Full psychiatric evaluation should be performed for those screened positive for depression as described in table (2) for diagnostic criteria of DLL.
Management of late life depression
The first priority in treating elderly with depression is starting a plan to keep patient safe, which means evaluating presence of suicidal thoughts and any previous attempts to commit suicide. If there is positive history about ending his/her life, then interferences to prevent suicide must be applied, including strong family support and ensure safety of surrounding environment via remove weapons or stockpiles of drugs. Prevalence of suicidal ideation and attempts are higher in later life than in younger age groups. (1)

Table 2: Diagnostic criteria of depression according to DSM-5 and ICD-10

<table>
<thead>
<tr>
<th>DSM-5</th>
<th>ICD-10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Core symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>Depressed mood</td>
<td>Depressed mood</td>
</tr>
<tr>
<td>Loss of interest or pleasure</td>
<td>Loss of interest or pleasure</td>
</tr>
<tr>
<td>Decreased energy or increased fatigability</td>
<td>Decreased energy or increased fatigability</td>
</tr>
<tr>
<td><strong>Other symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>Weight loss or weight gain, increased or decreased appetite</td>
<td>Decreased or increased appetite with corresponding weight gain</td>
</tr>
<tr>
<td>Insomnia or hypersomnia</td>
<td>Sleep disturbance of any type</td>
</tr>
<tr>
<td>Psychomotor agitation or retardation</td>
<td>Psychomotor agitation or retardation</td>
</tr>
<tr>
<td>Fatigue or loss of energy</td>
<td>Loss of confidence and self-esteem</td>
</tr>
<tr>
<td>Feelings of worthlessness or excessive or inappropriate guilt</td>
<td>Unreasonable feelings of self-reproach or excessive and inappropriate guilt</td>
</tr>
<tr>
<td>Diminished ability to think or concentrate or Indecisiveness</td>
<td>Diminished ability to think or concentrate</td>
</tr>
<tr>
<td>Recurrent thoughts of death, suicidal ideation, attempt, or plan</td>
<td>Recurrent thoughts of death or suicide or suicidal behavior</td>
</tr>
</tbody>
</table>

DSM-5 Diagnostic and Statistical Manual, Fifth Edition
ICD-10 International Classification of Diseases, Tenth Revision

Management of late life depression
The first priority in treating elderly with depression is starting a plan to keep patient safe, which means evaluating presence of suicidal thoughts and any previous attempts to commit suicide. If there is positive history about ending his/her life, then interferences to prevent suicide must be applied, including strong family support and ensure safety of surrounding environment via remove weapons or stockpiles of drugs. Prevalence of suicidal ideation and attempts are higher in later life than in younger age groups. (1)

Table 3: Lines of Management of Late Life Depression

<table>
<thead>
<tr>
<th>Non Pharmacological Treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ Psychotherapy</td>
</tr>
<tr>
<td>➢ Alternative And Complementary Medicine</td>
</tr>
<tr>
<td>➢ Electroconvulsive Therapy</td>
</tr>
<tr>
<td>➢ Tai Chi</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharmacological Treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ Standard Treatment</td>
</tr>
<tr>
<td>➢ Emerging Therapeutics</td>
</tr>
</tbody>
</table>

Non Pharmacological Management
i. Psychotherapy
Evidence-based guidelines for treatment of moderate to severe depression in older adults recommend antidepressants and psychotherapy as the first-line of treatment (45). The American Psychiatric Association reported that 52% of health care providers used a combination of standard medication and psychotherapy while, 39% of them reported prescription of medication only (46).

Many studies reported that older adults prefer psychological treatment compared to pharmacologic treatments (47) and a recent meta-analysis reported that psychotherapy may be more beneficial than antidepressants for older adults with dysthymia or subsyndromal depression (48).

ii. Cognitive therapy
Cognitive behavioral therapy was first developed by Beck in 1976 and recently many health care providers consider cognitive behavioral therapy one of the most important non pharmacological lines of management of depression as shown in table (3). It was built on the theory that how we interpret situations influences our mood and behaviors. Management techniques are designed to allow individuals to recognize maladaptive or distorted cognitions and learn to encounter them so as to diminish strength of emotion and challenging behaviors. Behavioral therapy for depression is grounded on the concept that depressed individuals involve in few pleasurable and/or mastery events and thus do not obtain reinforcement from their environment (49).

iii. Alternative and complementary medicine
Elderly patients are chiefly vulnerable to antidepressant adverse effects, such as gastritis, sedation, dry mouth and sexual dysfunction (50). Many older patients prefer alternative therapy and may be resistant to taking antidepressants because of stigma about mental disorders. (51)
a) Fish oil and omega 3

The omega-3 fatty acids, derived from fish oil, have also been widely studied in affective disorders, with more than 30 published clinical trials (52). Studies seem to support antidepressant efficacy, both as monotherapy and as augmentation of standard antidepressants. Recommended doses for depression based on clinical trials are roughly 1000 mg/d. There is at least one published clinical trial examining the omega-3 fatty acids in depressed elderly. Rondanelli and colleagues (53) carried out an 8-week, randomized, double-blind, and placebo controlled trial of an omega-3 preparation (2.5 g/d) against placebo in 46 depressed female nursing home residents, ages 66 to 95. The investigators found a significant improvement in depressive symptoms as well as in health related quality-of-life symptoms in the omega-3 group compared with the placebo group.

b) Folic Acid

There is accumulating evidence about association between depressive symptoms and low serum levels of folate (54). Multiple studies have examined different folic acid forms for antidepressant like effect predominantly in combination with standard agents, with promising results (55,56). The 5-MTHF (Deplin) was studied as an antidepressant adjunct therapy at doses of 15 mg/d. This form may be principally effective because it can cross the blood-brain barrier directly and deliver more active product.

c) Exercise

There is no doubt that, health benefits of regular physical exercise have long been known and scientifically supported for a variety of populations (57). Higher physical activity levels among elderly specifically may have a protective effect against development of depression (58). Recent results point to the potential usefulness of exercise as a treatment of depressive symptoms in older adults, in certain cases with similar efficacy to antidepressants. The design of exercise (ie, supervised or unsupervised) may be an important variable to be considered (59). Timonen and colleagues in 2002 compared supervised anaerobic exercise (ie, strength training) twice per week with unsupervised home-based exercise 2 to 3 times per week. Depressive symptoms were significantly reduced (P value = 0.048) for Members in the supervised exercise group compared with those in the unsupervised arm, suggesting that adherence to exercise regime, social support, or both may facilitate the effects of exercise on depressive symptom (60).

Pharmacological Treatment:

In the beginning of 1950s, the most effective antidepressants were classified into monoamine oxidase inhibitors and tricyclic antidepressants. These medications could improve affect in more than half of depressed patients after a few weeks of adherence. Almost all recent antidepressants were industrialized via minor modifications of original antidepressants act chiefly through mono-aminergic mechanisms. On the other hand, recent technology made marked reduction in side-effect profiles and overdose toxicity but these newer medications did not show significant difference in the efficacy and/or speed of its effect.

Standard Treatment

Most of the reviews did not find a discrepancy between different classes of antidepressants in elderly (61). However, in many studies directly comparing between TCAs and SSRIs, there was no difference in the efficacy profile. Unfortunately, most of these trials have been supported by a pharmaceutical company and presence of conflict of interest. In addition to that there is no concrete conclusion about which SSRI member should be the treatment of choice for depressed elderly. This is may be due to the equal side-effect profile of all SSRIs with little differences in drug-drug interactions as shown in table (4). Nortriptyline is a secondary amine which exhibit less orthostatic hypotension adverse effect than tertiary amines (e.g., amitryptiline) and is the TCA of choice in treating late life depression.

The usage of TCAs became more limited since SSRIs and other antidepressant explicit better safety profile. The main safety issue of TCAs is their serious cardiovascular side effect, including higher risk of sudden cardiovascular death especially if concomitant ischemic heart disease is present in addition to high mortality rate after an overdose. TCAs are not recommended as the first choice of treating depression in elderly. There are many anticholinergic adverse effects of TCAs including dry mouth, urinary retention, and cognitive impairment. So, orthostatic hypotension is problematic in elderly because of its higher risk of falls and other serious consequences that increases the overall morbidity and mortality but if there is a strong indication to continue the antidepressant (62).

Table 4: Common classes of antidepressant

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Sedation</th>
<th>Anti-cholinergic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine</td>
<td>5-20 mg</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sertraline</td>
<td>25-100 mg</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>10-20 mg</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Citalopram</td>
<td>10-40 mg</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>10-75 mg</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Desipramine</td>
<td>25-125 mg</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>15-45 mg</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Trazodone</td>
<td>50-300 mg</td>
<td>++++</td>
<td>+</td>
</tr>
<tr>
<td>Bupropion</td>
<td>75-150 mg</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>25-75 mg</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Emerging therapeutics:

I. Glutamatergic Drugs

There is accumulating evidence suggesting that alterations in the glutamatergic neurotransmitter system participate in the neurobiology of major depressive disorder (MDD)\(^{63,64}\). In animal studies, there is several reports that stress is associated with higher levels of glutamatergic activation in numerous brain regions \(^{65}\) contributing to various form of stress-related neurotoxicity \(^{66}\). In vivo magnetic resonance spectroscopy studies have established abnormal Glu content in various brain regions of patients with MDD \(^{67}\). For all these reasons, there is increased desire to synthesize pharmaceutical agents targeting the glutamatergic system for the treatment of MDD. The NMDA receptor has acquire significant attention All through the field of neuroscience because of its roles in learning neurotoxicity and Neuroplasticity. The receptor has numerous unique properties, such as the need for a co-agonist (glycine), the presence of multiple allosteric binding sites, a voltage sensitive blockage of the ion channel by magnesium and interactions with various scaffolding proteins that mediate the transport and localization of the receptor as well as interactions with multiple signaling, which make it well suited to playing a critical role in regulating neuroplastic changes.

An early report in this area by Skolnick \(^{68}\) suggested that the receptor may be a target of antidepressant action by showing that a drug’s ability to alter the NMDA receptor’s binding affinities was greatly associated to its antidepressant activity in the outpatient clinic. Interest in the NMDA receptor grew quickly after the unexpected finding that single subanesthetic dose (0.5 mg/kg over 40minutes) of ketamine which is noncompetitive NMDA receptor antagonist, created a rapid and sustained response in 7 individuals with previously treatment as resistant MDD \(^{69}\).

Although this promising results of these studies that explore potential development of NMDA antagonists as antidepressant agents, ketamine produces several acute adverse effects, such as disturbed consciousness, perceptual and cognitive alteration and increased blood pressure, that markedly limit its potential usefulness in the outpatient care system including the intravenous route of administration.

On the other hand, the finding that ketamine produces a rapid Mood Improvement after a single does not essentially mean that chronic administration will sustain the response. In fact, it is possible that chronic administration of NMDA antagonists could have damaging properties on neuronal survival. \(^{70}\)

II. mGluR Drugs

Group II metabotropic receptors (mGluR2 and mGluR3) are principally present on the presynaptic membrane in addition to glial cells, where they are supposed to modulate Glu neurotransmission by sensing Glu Spillover and regulating transmitter release. Recent study has suggested that the group II metabotropic receptors also provide a vital role in the mechanisms of neuroprotection and neurodegeneration \(^{71}\). The role of the mGlu2/3 receptors in controlling Glu neurotransmission makes them extremely motivating targets for antidepressant drug advance, and rapidly accumulating evidence advocates that drugs targeting the mGluR2/3 receptors exhibit both antidepressant and anxiolytic properties \(^{72,73}\). Riluzole (Rilutek), a drug currently Food and Drug Administration-approved and marketed for the treatment of amyotrophic lateral sclerosis, \(^{74}\), has gained considerable attention. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) appears to modulate Glu neurotransmission by numerous pharmacological mechanisms. The drug was originally developed as an anticonvulsant, and early studies showed it to oppose several actions of Glu in vitro and in vivo\(^{75}\). Following an initial case report of a patient with comorbid obsessive compulsive disorder and MDD who appeared to experience a clinical benefit in both mood and obsessive-compulsive disorder symptoms after starting riluzole, \(^{76}\) there have been several additional reports of open-labeled clinical trials suggesting that riluzole possesses potent antidepressant and anxiolytic properties.

An initial open-label clinical trial investigative the effects of riluzole in 19 treatment-resistant depressed patients found a major improvement in mood evaluations beginning in the third week of treatment \(^{77}\). A more recent study demonstrated that riluzole augmentation of traditional antidepressant medications produced a significant improvement in depressive symptoms in 10 subjects with severe treatment-resistant depression \(^{78}\). Moreover, subjects who achieved a remission in the initial 6-week phase of this study sustained their remission for the 3-month duration of the study.

III. Melatonin:

Melatonin, a tryptophan-derived hormone released chiefly from the pineal gland, is a vital regulator of sleep/wake cycles \(^{79}\). Also, melatonin release is synchronized to a 24-hour cycle via light exposure \(^{80}\). Apart from sleep disturbance associated with depression, it is not astonishing that melatonin has been greatly examined in depression research. Both the concentration of melatonin and the timing of melatonin release are disturbed in depression \(^{81}\). Additionally, close adherence to antidepressants medications results in increased melatonin levels \(^{80}\).

In general, the administration of melatonin itself has not shown consistent efficacy in major depression \(^{82}\). This disappointing result has increased interest in the use of agomelatine, a melatonin receptor agonist. Like familiar antidepressants, prolonged agomelatine treatment results in increased hippocampal neurogenesis \(^{83}\).
Loo and colleagues in 2002 conducted a double-blind, placebo-controlled trial of agomelatine including 711 patients with MDD and found that 25 mg of agomelatine was significantly more effective than placebo. A second double-blind, placebo-controlled trial confirmed the efficacy of agomelatine, and a pooled analysis confirmed the overall effect \(^{(84)}\). Together, these findings have raised substantial hope that agomelatine will prove to be an effective antidepressant, possibly with a faster onset of action than current antidepressants. It is important to note that the long-term efficacy and tolerability of agomelatine have not yet been reported.

IV. **Triple reuptake inhibitors**

After the established success of the serotonin-norepinephrine reuptake inhibitors (SNRI) in treatment of MDD, researchers have tracked the idea of developing one agent that can block all three monoamine transporters, the so-called 5-HT, NE, DA reuptake inhibitors (SNDRIs), or triple reuptake inhibitors. This hypothesis was based on the positive role of DA on the reward system and the fact that anhedonia is a prominent symptom in a subset of MDD patients \(^{(85)}\). This theory was further reinforced by positive clinical augmentation studies with DA-enhancing drugs \(^{(86)}\).

During the past decade, several SNDRI drug members have been tested in the clinic. The main worries with these drugs were how to avoid excessive dopaminergic stimulation and possibility of drug abuse. Amitifadine (DOV-219474 or EB-1010), which was among the first SNDRI drug candidates, preferentially enhanced 5-HT with 1:2:8 potency rankings for the inhibition of SERT, NET, and DAT, respectively \(^{(87)}\). Amitifadine showed efficacy in a small clinical proof-of-concept (PoC) study. However, amitifadine did not meet the clinical endpoint in a subsequent larger double-blind placebo-controlled study in MDD patients who had failed one treatment with a first-line antidepressant. Extra clinical studies in MDD are being planned with this compound at higher doses. Other efforts to develop more balanced SNDRIs with similar Ki values for SERT, NET, and DAT have also failed, in most cases before reaching PoC studies.

Two compounds, NS-2359 (GSK-372475) and liafensine (BMS-820836), were evaluated in phase 2 clinical studies, but unfortunately both programs were terminated. In a large phase 2 program with 900 patients, NS-2359 was found neither efficacious nor well tolerated, whereas comparators venlafaxine and paroxetine separated significantly from placebo \(^{(87)}\).

Thus, in spite of significant investments, the clinical value of SNDRIs for the treatment of depression remains to be demonstrated. There are still several SNDRIs in preclinical development (e.g., LPM570065) \(^{(88)}\) that might be clinically tested at a later time. However, the disappointment of the DA-releasing compound lisdexamfetamine to show efficiency as adjunctive therapy in MDD patients who responded insufficiently to monotherapy with an SSRI or SNRI is not helpful of a role of enhanced DA transmission in promoting antidepressant property. SNDRIs might have better efficacy in a well-defined subset of MDD patients with prominent symptoms of anhedonia. This remains to be substantiated in future clinical studies.

V. **Anticholinergic mechanism**

Another cholinergic mechanism that has been revealed for the treatment of MDD depended on the modulation of nicotinic cholinergic receptors \(^{(89)}\). Both nicotinic antagonists and partial agonists have been tested in clinical trials, but with limited success. A clinical study of the a4b2 nicotinic cholinergic receptor antagonist TC-5214 (the S-enantiomer of mecamylamine) as an add-on treatment to SSRIs was promising, but unfortunately the further clinical studies were unsuccessful to explore this result and the development program was aborted \(^{(90)}\).

VI. **Opioid antagonists**

Another approach that has recently obtained substantial interest is kappa opioid antagonists. Increase of dynorphin release, the endogenous ligand for the kappa opioid receptor, has been found to cause dysphoria in humans after chronic stress exposure. Furthermore, preclinical studies have verified that dynorphin can reduce dopamine release in the nucleus accumbens and thereby cause anhedonia-like symptoms \(^{(91)}\).

ALKS-5461, a combination of buprenorphine (partial m opioid receptor agonist, kappa opioid receptor antagonist) and samidorphan (m opioid antagonist), has shown optimistic results in a phase 2 study and is currently in phase 3 as an augmentation therapy for the treatment of TRD (https://clinicaltrials.gov/show/NCT02158533).

VII. **Neuro-inflammation**

Another biology linked to MDD is the chronic elevated inflammatory cytokines, has been an area of interest for some time. The interest has been powered by numerous studies signifying that depressed patients have elevated serum levels of pro-inflammatory cytokines, notably IL-6 and TNF-α \(^{(92)}\).

Cyclooxygenase-2 (COX-2) inhibitors that decrease production of prostaglandine E\(_2\) and pro-inflammatory cytokines have been examined in a number of clinical trials of MDD. The frequently tested drug celecoxib, exposed antidepressant efficacy as an add-on therapy to reboxetine \(^{(93)}\) fluoxetine \(^{(94)}\) and sertraline in three small double-blind placebo controlled trials.

In single study, the adjunctive therapy with celecoxib reduced IL-6 blood levels in depressed patients, and there was a substantial correlation between the decrease in Hamilton Depression Rating Scale scores and IL-6 serum levels after six weeks of treatment \(^{(95)}\). In preclinical study, celecoxib was shown to augment the effects of fluoxetine and sertraline on cortical NE and 5-HT levels in rats which might afford mechanistic support for its antidepressant efficacy \(^{(96)}\).

In addition to combined treatments with COX-2 inhibitors, the potential of a TNF-α antibody as...
monotherapy has been evaluated in TRD patients in one clinical trial (97).

In that study, the TNF-α antibody, infliximab, did not differ from the placebo, but did show a trend toward antidepressant activity in patients with elevated levels of inflammatory biomarkers at baseline (97). These results indicate that anti-inflammatory agents should be further examined as treatment options for MDD, especially in patients with comorbid inflammatory diseases and high levels of inflammatory cytokines.

Prognosis

DLL leads to multiple negative consequences, such as disability, cognitive impairment, deterioration in comorbid physical disorders, and an increased risk of mortality. Remission rates of DLL after treatment is similar to that of younger age groups; however, relapse rates are higher. The risk of relapse is highest for the first 6 months. Hence, treatment should be continued for 6–9 months. (7)

Even after the first depressive episode in old age, the relapse rate is high after the treatment has been discontinued. So, lifelong maintenance treatment is recommended even if the first depressive episode has a later onset for severe cases. Cautions regarding polypharmacy, side effects, and other risk factors for relapse, such as cerebrovascular pathology, other physical diseases, and cognitive impairment should be considered.

Summary:

DLL is a common problem in geriatrics clinic. It is usually underreported and under recognized due to atypical signs and symptoms of depression. DLL is attributed to complex bio-psychosocial factors. Initial screening, followed by a more thorough physical examination and mental health interview, should be the mainstay of geriatric clinicians’ practice. Different modalities of therapy should be considered based on efficacy, side effects, tolerability and patients’ comorbid profiles.

References:


88) Zhang R., X. Li, Y. Shi, Y. Shao, K. Sun, A. Wang, et al., The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats, PLOS ONE 2014; e91775.


91) A.T. Knoll, W.A. Carlezon Jr., Dynorphin, stress, and depression, Brain Res. 2010. 1314 ; 56–73.


